Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Renal cell carcinoma

Therapy with mind and system

    • Education
    • Nephrology
    • Oncology
    • RX
  • 2 minute read

Renal cell carcinoma is one of the common malignant tumors in adults. In terms of drug treatment options, this tumor entity has undergone more rapid change in recent years than almost any other malignant disease. Meanwhile, the focus is not only on targeted therapy in advanced renal cell carcinoma, but also on combination treatments.

Kidney cancer is the third most common urologic cancer. Every year, nearly 1000 people in Switzerland develop a malignant renal tumor [1]. The majority of tumors histologically belong to the clear cell renal carcinomas, which – depending on the subtype – have a slightly better prognosis than non-clear cell renal cancer [2]. However, in the advanced stage, the prognosis is unfavorable for most affected individuals: three quarters of them have a moderate to high risk of the disease not stopping [3]. Numerous new approvals have significantly changed the therapeutic landscape for metastatic renal cell carcinoma. Targeted therapies were joined by immune checkpoint inhibitors, which can now be used in combination [4].

Targeted therapy with tyrosine kinase inhibitors, mTOR inhibitors or antibodies has become established in recent years. Most notably, vascular endothelial growth factor receptor (VEGFR) inhibition is the standard option for patients with favorable prognosis whose tumors have failed surgery or have metastasized [5] (Tab. 1). The first checkpoint inhibitor, targeting the surface protein PD-1, was then approved as second-line therapy after failure of prior therapy. Recently, dual immune checkpoint blockade has also become possible in earlier use. The combination therapy of the checkpoint inhibitor nivolumab with the antibody ipilimumab directed against CTLA-4 was approved. Compared with targeted therapy, dual checkpoint blockade shows advantages in patients with intermediate or unfavorable baseline risk. At 18 months, 75% of those affected were still alive and median overall survival was not achieved during the study observation period. In 9% of those treated with immunotherapy, the disease responded completely to treatment, and the tumor was therefore initially undetectable after therapy [3]. However, the chance of achieving an optimal response and a long-lasting remission with the new therapeutics is accompanied by a high rate of side effects. Their treatment requires a well-coordinated interdisciplinary treatment team [4].

 

 

The future: combination therapies

A new way of immuno-oncological treatment of renal cancer is to combine the established targeted substances with the still relatively new checkpoint inhibitors. In America, the new mode of action consisting of, for example, the tyrosine kinase inhibitor axitinib with pembrolizumab (anti-PD-1 antibody) or axitinib with the also anti-PD-L1 antibody avelumab has already been approved. In Europe, approval is eagerly awaited.

 

Literature:

  1. www.krebsliga.ch/ueber-krebs/zahlen-fakten/-dl-/fileadmin/downloads/sheets/zahlen-krebs-in-der-schweiz.pdf (last accessed 15.30.2020)
  2. www.krebsinformationsdienst.de/fachkreise/nachrichten/2019/fk17-nierenkrebs-immuntherapie-kombination.php (last accessed 15.30.2020)
  3. Motzer RJ, Nizar M, Tannier MD, et al: Nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. N Engl J Med 2018; 378: 1277-1290.
  4. Zschäbitz S, Ivanyi P, Delecluse S: Revolution in systems therapy of metastatic renal cell carcinoma. The Nephrologist 2020; 15: 12-19.
  5. Ivanyi P, Grünwald V: Systems therapy of renal cell carcinoma. Oncologist 2019; 25: 517-522.
  6. Heng DYC, Xie W, Regan MM, et al: External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14: 141-148.

 

InFo ONCOLOGY & HEMATOLOGY 2020; 8(2): 23.

Autoren
  • Leoni Burggraf
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • Kidney cancer
  • renal cell carcinoma
Previous Article
  • Migraine

Common genetic variables to MS detected

  • Genetics
  • Neurology
  • RX
  • Studies
View Post
Next Article
  • Atopic dermatitis

Emollients – still a central element of basic therapy

  • Allergology and clinical immunology
  • Dermatology and venereology
  • Education
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.